The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1457
December 8, 2014
View Complete Issue         Table of Contents 2019 
Two New Drugs for Idiopathic Pulmonary Fibrosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two New Drugs for Idiopathic Pulmonary Fibrosis
December 8, 2014 (Issue: 1457)
The FDA has approved 2 oral drugs for treatment of idiopathic pulmonary fibrosis (IPF). Pirfenidone (Esbriet) has been available in Europe since 2011 and in Canada since 2012. Nintedanib (Ofev) is available only in the US.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Drugs for Idiopathic Pulmonary Fibrosis
Article code: 1457b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.